Linkage Tool for the ERDERA Clinical Trial Call 2026
Overview
The ERDERA Clinical Trial Call 2026 (ECTC 2026) is led by the European Rare Diseases Research Alliance (ERDERA), in partnership with the CIHR Institute of Genetics. The objective of this funding opportunity is to support multinational, GCP-compliant Phase I, Phase I/II, and Phase II interventional clinical trials in the field of rare diseases. More information about the ECTC 2026 is available on the ERDERA website. Information on CIHR ResearchNet for Canadian researchers will be published at a later date.
To achieve the objectives of ECTC 2026, strong connections and collaborations must be established between applicants in Canada and other ERDERA eligible countries. One of the ways CIHR is supporting the development of such connections is through this linkage tool, which aims to facilitate the formation of international research teams (consortia) and the development of joint applications.
Notice
Important: To be included in the linkage tool, please complete this short form. Your information will be added to the table below during the next update. Please note that this is not a mandatory step.
This form can be completed by researchers/investigators in Canada and other ERDERA eligible countries who are interested in sharing information and/or establishing collaborations for this funding opportunity.
Information is posted in the language in which it was submitted. It is provided on a voluntary basis and in no way confers any advantages in the evaluation and/or funding of applications.
We encourage you to explore the table below and connect with any people/groups that align with your interests to discover potential synergies and collaboration opportunities. The table will usually be updated weekly, until October 2027 and regularly thereafter.
| Contact information | Expertise | Condition(s) / Disease Area(s) | Intervention Type(s) | Target Population(s) |
|---|---|---|---|---|
| Tamorah Lewis tamorah.lewis@sickkids.ca The Hospital for Sick Children Researcher, Practitioner/Physician Ontario Canada 416-813-2143 |
Neonatology and Pediatric Clinical Pharmacology - PK/PD studies, pharmacogenetics, drug toxicity, precision medicine | Neonatal disease, pediatric rare disease | Small molecules, medical devices | Fetus, neonate, children |
| Breanne Stewart breanne.stewart@micyrn.ca RareKids-CAN Director- Pediatric Rare Disease Clinical Trials and Treatment Network AB Canada |
Consultation services for the following areas: study design, outcomes, biostatistics, pharmacology, registry and natural history, real world data and evidence, patient and family engagement, knowledge translation/mobilization, equity diversity & inclusivity, Indigeneity, sex & gender, transition to adulthood/youth perspectives, validated database & data management, training & mentorship. Site & Investigator Identification across 16 pediatric research institutes & affiliated across Canada | Disease/condition agnostic (excluding oncology) | Any (open to all intervention types) | Fetuses, neonates, children, adolescents, young adults |
|
Aiman Siddiqi aiman.siddiqi@micyrn.ca Director of Clinical Research Maternal Infant Child and Youth Research Network (MICYRN) BC Canada |
Pre-funding services: Consultation, study design and protocol optimization, letters of support. Post funding: Protocol development, Health Canada regulatory submission, centralized ethics submission, bilingual monitoring, quality assurance, DSMB project management support, biostatistical design & analysis, knowledge translation & communications, patient & family engagement, administration, finance and governance of grants, database support. |
Any | Any (open to all interventions types) | Fetuses, neonates, children, adolescents, young adults |
|
Fausto Queda fqueda@vectorb2b.com VectorB2B Senior Project Manager - CTMO Portugal |
Clinical development and trial management experience across infectious diseases, oncology, ophthalmology, medical devices, and biologics. Expertise includes observational studies, in vitro and in vivo efficacy studies, ADME and pharmacokinetic (PK) studies, feasibility assessments, regulatory submissions, and the implementation and coordination of multicentre national and international clinical trials ranging from Phase I to Phase III. Therapeutic areas include diabetic foot infections, ventilator-associated pneumonia, neurotrophic keratopathy, and spinal cord injury. | Any | To be determined | To be determined |
|
Hernan Gonorazky hernan.gonorazky@sickkids.ca Practitioner/Physician, Researcher The Hospital for Sick Children (SickKids) Ontario Canada |
Methodological expertise: Precision medicine and advanced therapeutics clinical trials, including gene therapy, gene editing, antisense oligonucleotide (ASO) therapies, small molecules, and drug repurposing; clinical trial design, operations, and coordination; natural history studies and patient registries; clinical outcome assessment selection and validation; biomarker identification and development; and translational research in rare genetic disorders Clinical expertise: Genetics, neurology, neuromuscular disorders, neurodegenerative disorders, rare diseases |
Rare and ultra-rare paediatric neuromuscular and neurodegenerative disorders, such as muscular dystrophies (e.g. DMD, LGMD, MDC1A), spinal muscular atrophy (SMA), congenital myopathies (e.g. MTM, NM), inherited peripheral neuropathies (e.g. CMT), and lysosomal storage disorders with CNS involvement | Any (open to all intervention types) | Children and adolescents (birth to 18 years of age) with neuromuscular/neurodegenerative disorders |
| Robert Hamilton robert.hamilton@sickkids.ca Hospital for Sick Children (SickKids) Ontario Canada |
Biomarkers (including companion), mechanisms, precision medicine, registry, natural history and real world data for rare cardiac disorders affecting children and young adults, particularly inherited arrhythmia and arrhythmogenic cardiomyopathy syndromes. Acquired cardiac conduction disorders. | Arrhythmogenic Cardiomyopathy, Brugada syndrome, Catecholaminergic Polymorphic Ventricular Tachycardia, Calmodulinopathy, TECRL mutations, Triadin Knockout Syndrome. Acquired cardiac conduction disorders: Autoimmune Congenital Heart block, Chagas disease and Lyme disease | Any | Fetuses, neonates, children, adolescents, young adults |
| Jacob Jaya jacob.jaya@insilicotrials.com Strategic Partnerships InSilicoTrials Italy |
Methodological expertise: In silico clinical trial design and analysis for rare and pediatric populations, including virtual patients, digital twins, synthetic control arms, MIDD, PK/PD and systems pharmacology modelling, cardiac safety assessment, and regulatory-grade evidence generation. Expertise also includes the use of natural history and real-world data to create external comparators. Clinical expertise: Applied modelling experience in cardiology, cardiac safety, metabolic and neuromuscular disorders, and rare pediatric diseases. We act as a methodological partner and collaborate with clinical experts for trial leadership and disease-specific input. |
Cardiovascular hypertrophic and other cardiomyopathies, inherited arrhythmia syndromes and channelopathies (e.g. long QT syndrome), and drug-induced proarrhythmia / cardiac safety. Broader interest and experience in paediatric and orphan rare genetic diseases, and openness to metabolic and neuromuscular conditions where quantitative modelling adds value. | Any (open to all intervention types) | Across the lifespan, with particular experience in paediatric populations (neonates, children, adolescents) and adults. |
- Date modified: